{"id":"W2884001607","doi":"10.1016/s1470-2045(18)30333-4","title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Nova (rocket); Placebo; Double blind; Medicine; Quality of life (healthcare); Oncology; Gynecology; Ovarian cancer; Internal medicine; Cancer; Alternative medicine; Pathology; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001775898,0.0003052381,0.002146879,0.000138256,0.0000806962,0.00001201358,0.0002368618,0.0002230145,0.0004247515],"category_scores_gemma":[0.000397204,0.0001708364,0.0001103099,0.0004656774,0.0005610806,0.00006545037,0.00002790394,0.0004410187,0.00001157498],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004680573,"about_ca_system_score_gemma":0.001022847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003095391,"about_ca_topic_score_gemma":0.005931935,"domain_scores_codex":[0.9963817,0.001046821,0.001145069,0.0004896753,0.0004835005,0.0004532484],"domain_scores_gemma":[0.9958993,0.00166862,0.001072239,0.0007339268,0.0004651676,0.0001607214],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9873922,0.002152664,0.003856843,0.00001518319,0.001082883,0.000006979711,0.001341804,0.00001677478,0.0001985806,0.00004968534,0.001749495,0.002136841],"study_design_scores_gemma":[0.9744719,0.01679018,0.005176454,0.0001577368,0.0003241983,6.905869e-7,0.00008920494,0.00007157285,0.0005652569,0.00002085211,0.002127279,0.000204733],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820429,0.0001041194,0.00006343582,0.003125781,0.0008713175,0.007880219,0.0003301348,0.00005879268,0.005523312],"genre_scores_gemma":[0.9955879,0.00007016075,0.0002624704,0.0006901856,0.001648259,0.001366333,0.0002770337,0.00003251456,0.00006518083],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01463752,"threshold_uncertainty_score":0.6966505,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1468114558995152,"score_gpt":0.4253526568431366,"score_spread":0.2785412009436214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}